Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: A randomized, double-blind, placebo-controlled crossover study

Journal of Clinical Psychiatry

Volumn 68, Issue 7, 2007, Pages 1031-1037

  Libov, Igor ^b   Miodownik, Chanoch ^b   Bersudsky, Yuly ^b   Dwolatzky, Tzvi ^b   Lerner, Vladimir ^a  

^a MENTAL HEALTH CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PIRACETAM; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL HOSPITAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA; TREATMENT DURATION;

EID: 34548316587     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0709     Document Type: Article

References (56)

1. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(suppl 4):5-9
2. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, pt 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547
3. Peroutka SJ, Synder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 1980;137:1518-1522
4. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry 1993;34:713-738
5. Andersson U, Haggstrom JE, Levin ED, et al. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Mov Disord 1989;4:37-46
6. Cadet JL, Kahler LA. Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994;18:457-467
7. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;4:CD000209
8. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-1052
9. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-1514
10. Caroff SN, Campbell EC, Havey J, et al. Treatment of tardive dyskinesia with donepezil: a pilot study. J Clin Psychiatry 2001;62:772-775
11. Bergman J, Dwolatzky T, Brettholz I, et al. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders. J Clin Psychiatry 2005;66:107-110
12. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 2003;160:1117-1124
13. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281
14. Barnes TR, Kidger T. Clonazepam and tardive dyskinesia. Am J Psychiatry 1981;138:1127-1128
15. Bobruff A, Gardos G, Tarsy D, et al. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry 1981;138:189-193
16. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59:S22-S26
17. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002;18:201-208
18. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481
19. Chouinard G, Annable L, Mercier P, et al. Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987;23:221-226
20. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994;55(suppl B):102-106
21. Giurgea C, Salama M. Nootropic drugs. Prog Neuropsychopharmacol 1977;1:235-247
22. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Brain Res Rev 1994;19:180-222
23. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 2005;11:169-182
24. Winnicka K, Tomasiak M, Bielawska A. Piracetam - an old drug with novel properties? Acta Pol Pharm 2005;62:405-409
25. Ricci S, Celani MG, Cantisani AT, et al. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev 2006;2:CD000419
26. Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 1989;13(suppl):S77-S88
27. Pilch H, Muller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology (Berl) 1988;94:74-78
28. Noorbala AA, Akhondzadeh S, Davari-Ashtiani R, et al. Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia. J Clin Pharm Ther 1999;24:369-374
29. Gobert JG. Genesis of a drug: piracetam: metabolism and biochemical research. J Pharm Belg 1972;26:281-304
30. Tacconi M, Wurtman R. Piracetam: physiological disposition and mechanism of action. In: Fahn S, ed. Advances in Neurology. New York, NY: Raven Press; 1986
31. Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64:344-348
32. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609
33. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000;61(suppl 4):39-44
34. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000;33(suppl 1):14-33
35. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, pt 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714
36. Sikora J, Kabes J, Pisvejc J. Management of neuroleptic side-effects with piracetam (author trans). Cesk Psychiatr 1981;77:137-142
37. Kabes J, Sikora J, Pisvejc J, et al. Effect of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatry 1982;17:185-192
38. Kabes J, Sikora J, Stary O, et al. Effectiveness of piracetam in tardive dyskinesia-double-blind cross-over controlled trial with a placebo. Cesk Psychiatr 1983;79:339-345
39. Chaturvedi SK. Piracetam for drug-induced dyskinesia [letter]. J Clin Psychiatry 1987;48:255
40. Obeso JA, Artieda J, Quinn N, et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11:529-536
41. Piperidou C, Maltezos E, Kafalis G, et al. Piracetam for choreoathetosis. Lancet 1988;2:906
42. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21
43. Fehr C, Dahmen N, Klawe C, et al. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol 2001;21:248-249
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
45. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
46. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265
47. Hyde TM, Egan MF, Brown RJ, et al. Diurnal variation in tardive dyskinesia. Psychiatry Res 1995;56:53-57
48. StatSoft. Statistica 7 for Windows. Electronic Statistics Textbook. Available at: http://www.statsoft.com/textbook/stathome.html. Accessed March 22, 2007
49. Milliken GA, Johnson DE. Analysis of Messy Data, Volume 1: Designed Experiments. New York, NY: Chapman & Hall; 1992
50. DeVeaugh-Geiss J, Manion L. High-dose pyridoxine in tardive dyskinesia. J Clin Psychiatry 1978;39:573-575
51. Devaux A. Dyskinesies tardives: role de la pyridoxine dans la prevention. Semin Hop Paris 1987;63:1476-1480
52. Lerner V, Liberman M. Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. J Clin Psychiatry 1998;59:623-624
53. Lerner V, Kaptsan A, Miodownik C, et al. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999;22:241-243
54. Horvath B, Marton Z, Halmosi R, et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 2002;25:37-42
55. Yassa R, Lal S, Korpassy A, et al. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987;22:67-72
56. Menza MA, Grossman N, Van Horn M, et al. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991;30:109-115